William E Boden

Summary

Affiliation: State University of New York at Buffalo
Country: USA

Publications

  1. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
  2. ncbi Interpreting the results of the COURAGE trial: a non-interventionalist perspective
    William E Boden
    Department of Medicine and Preventive Medicine, University at Buffalo School of Medicine, and Buffalo General Hospital, Buffalo, NY, USA
    Rev Cardiovasc Med 10:S34-44. 2009
  3. ncbi Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options
    William E Boden
    School of Medicine and Biomedical Sciences, State University of New York, and Kaleida Health System, Buffalo, New York, USA
    J Am Coll Cardiol 50:917-29. 2007
  4. ncbi Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
    William E Boden
    VA Western New York Health Care System, Buffalo General Hospital, and the University at Buffalo, Buffalo, NY, USA
    Am J Cardiol 104:1-4. 2009
  5. doi Reperfusion strategies in acute ST-segment elevation myocardial infarction
    William E Boden
    Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health, Buffalo, NY 14203, USA
    Curr Opin Cardiol 23:613-9. 2008
  6. ncbi Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective
    William E Boden
    Buffalo General Hospital and SUNY, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA
    Cardiovasc Drugs Ther 24:207-16. 2010
  7. ncbi Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis
    William E Boden
    Department of Cardiology, Buffalo General and Millard Fillmore Hospitals and Division of Cardiovascular Medicine, Schools of Medicine and Public Health, State University of New York at Buffalo, NY, USA
    Crit Pathw Cardiol 9:116-25. 2010
  8. doi Management of chronic coronary disease: is the pendulum returning to equipoise?
    William E Boden
    University at Buffalo Schools of Medicine and Public Health, 100 High Street, Buffalo, NY 14203, USA
    Am J Cardiol 101:69D-74D. 2008
  9. doi ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy
    William E Boden
    Buffalo General Hospital, Buffalo, NY, USA
    Am J Emerg Med 26:212-20. 2008
  10. ncbi Interpreting the COURAGE trial. It takes COURAGE to alter our belief system
    William E Boden
    University at Buffalo Schools of Medicine and Public Health, Buffalo General and Millard Fillmore Hospitals, Buffalo, NY 14203, USA
    Cleve Clin J Med 74:623-5, 629-33. 2007

Detail Information

Publications74

  1. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....
  2. ncbi Interpreting the results of the COURAGE trial: a non-interventionalist perspective
    William E Boden
    Department of Medicine and Preventive Medicine, University at Buffalo School of Medicine, and Buffalo General Hospital, Buffalo, NY, USA
    Rev Cardiovasc Med 10:S34-44. 2009
    ..The important quality-of-life findings permit physicians to engage in an evidence-based discussion with patients about the expected clinical and health status benefits of initial versus deferred PCI when added to OMT...
  3. ncbi Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options
    William E Boden
    School of Medicine and Biomedical Sciences, State University of New York, and Kaleida Health System, Buffalo, New York, USA
    J Am Coll Cardiol 50:917-29. 2007
    ..Results from ongoing clinical trials will provide guidance regarding the utility of this strategy...
  4. ncbi Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
    William E Boden
    VA Western New York Health Care System, Buffalo General Hospital, and the University at Buffalo, Buffalo, NY, USA
    Am J Cardiol 104:1-4. 2009
    ....
  5. doi Reperfusion strategies in acute ST-segment elevation myocardial infarction
    William E Boden
    Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health, Buffalo, NY 14203, USA
    Curr Opin Cardiol 23:613-9. 2008
    ....
  6. ncbi Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective
    William E Boden
    Buffalo General Hospital and SUNY, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA
    Cardiovasc Drugs Ther 24:207-16. 2010
    ....
  7. ncbi Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis
    William E Boden
    Department of Cardiology, Buffalo General and Millard Fillmore Hospitals and Division of Cardiovascular Medicine, Schools of Medicine and Public Health, State University of New York at Buffalo, NY, USA
    Crit Pathw Cardiol 9:116-25. 2010
    ..Patients without prior cardiovascular intervention had a lower intensity of risk factor modification at baseline and appear to represent an at-risk, undertreated population...
  8. doi Management of chronic coronary disease: is the pendulum returning to equipoise?
    William E Boden
    University at Buffalo Schools of Medicine and Public Health, 100 High Street, Buffalo, NY 14203, USA
    Am J Cardiol 101:69D-74D. 2008
    ..Thus, the treatment pendulum may be swinging back to the understanding that "best practice" today requires the judicious use of interventional and medical therapies in the appropriate patient population...
  9. doi ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy
    William E Boden
    Buffalo General Hospital, Buffalo, NY, USA
    Am J Emerg Med 26:212-20. 2008
    ..Recent trials support the development of an early and aggressive approach to more complete platelet inhibition using clopidogrel, in combination with ASA, for patients with STEMI...
  10. ncbi Interpreting the COURAGE trial. It takes COURAGE to alter our belief system
    William E Boden
    University at Buffalo Schools of Medicine and Public Health, Buffalo General and Millard Fillmore Hospitals, Buffalo, NY 14203, USA
    Cleve Clin J Med 74:623-5, 629-33. 2007
  11. ncbi The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    William E Boden
    VA Connecticut Healthcare System, West Haven, Connecticut, USA
    Am J Cardiol 99:208-12. 2007
    ....
  12. ncbi Acute coronary syndromes: selective vs early invasive strategies
    William E Boden
    Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health, Division of Cardiology, Buffalo General Hospital, 100 High Street, Buffalo, NY 14203, USA
    Clin Cardiol 32:621-6. 2009
    ..To facilitate this goal, we examined key differences between the 2002 and 2007 guidelines and explored data underlying changed recommendations for periprocedural pharmacotherapy...
  13. ncbi Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
    William E Boden
    VA Connecticut Healthcare System, West Haven, CT, USA
    Am Heart J 151:1173-9. 2006
    ....
  14. ncbi Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention
    William E Boden
    Division of Cardiology, Hartford Hospital, Hartford, Connecticut, USA
    J Am Coll Cardiol 41:1S-6S. 2003
  15. ncbi Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals
    Craig I Coleman
    Division of Cardiology, Hartford Hospital, Hartford, CT 06102 5037, USA
    Clin Ther 28:1054-62. 2006
    ..This approach, however, has not been systematically evaluated...
  16. ncbi Medical therapy in acute coronary syndromes: which medicines and at what doses?
    Dmitriy Kireyev
    Division of Cardiology, Buffalo General Hospital, Buffalo, NY 14203, USA
    Curr Cardiol Rep 11:267-75. 2009
    ..This is an exciting time to be involved in the field of cardiovascular medicine, as we continue to see profound improvement from medical therapy in the morbidity and mortality associated with ACS...
  17. ncbi The evolving role of medical therapy for chronic stable angina
    Freidy Eid
    Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203, USA
    Curr Cardiol Rep 10:263-71. 2008
    ....
  18. ncbi Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease
    Steven P Sedlis
    New York University School of Medicine, New York, NY, USA
    Am J Cardiol 104:1647-53. 2009
    ..Although PCI did not reduce the risk of death or myocardial infarction when added to OMT for patients with CKD, it also was not associated with worse outcomes in this high-risk group...
  19. doi Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Department of Medicine, Division of Cardiovascular Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Eur Heart J 29:2480-8. 2008
    ..We sought to determine the prevalence and prognostic significance of low HDL cholesterol levels in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  20. doi Risk factor control for coronary artery disease secondary prevention in large randomized trials
    Michael E Farkouh
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Coll Cardiol 61:1607-15. 2013
    ....
  21. doi The role of revascularization versus medical therapy in patients with type 2 diabetes mellitus and coronary artery disease
    Brian J Page
    Division of Cardiology, Buffalo General Hospital, 100 High Street, Buffalo, NY 14203, USA
    Curr Diab Rep 10:10-5. 2010
    ..Ongoing trials of diabetic patients with CAD randomized to PCI or CABG will help further elucidate the role of PCI with DES as a potential revascularization option for this patient population...
  22. doi Signs and symptoms of suspected myocardial ischemia in women: results from the What is the Optimal Method for Ischemia Evaluation in WomeN? Trial
    Jennifer H Mieres
    North Shore University Hospital, Manhasset, New York, USA
    J Womens Health (Larchmt) 20:1261-8. 2011
    ....
  23. ncbi Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management
    William E Boden
    Division of Cardiology, Hartford Hospital, Hartford, CT 06102 5037, USA
    Curr Opin Cardiol 18:278-85. 2003
    ....
  24. ncbi Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory
    Richard A Kerensky
    Malcom Randall Veterans Affairs Medical Center and the University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 39:1456-63. 2002
    ..We sought to determine the underlying coronary anatomy and characterize the culprit lesion after non-Q-wave myocardial infarction (NQWMI)...
  25. ncbi Emerging medical treatment for angina pectoris
    Stanley F Fernandez
    State University of New York at Buffalo, Division of Cardiovascular Medicine, 100 High St, Buffalo, 14203, NY, USA
    Expert Opin Emerg Drugs 15:283-98. 2010
    ..Despite improved mortality and morbidity in the treatment of coronary artery disease, a significant proportion of patients will continue to experience recurrent angina pectoris...
  26. ncbi Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes
    William E Boden
    Division of Cardiology, Department of Medicine, Buffalo General Hospital and Kaleida Health, State University of New York SUNY at Buffalo School of Medicine and Biomedical Science, Buffalo, NY 14203, USA
    Prog Cardiovasc Dis 50:311-51. 2008
    ....
  27. doi Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials
    Stanley F Fernandez
    Division of Cardiovascular Medicine, University at Buffalo and Buffalo General Hospital, University at Buffalo School of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
    Curr Atheroscler Rep 12:423-31. 2010
    ..For diabetic patients who have extensive coronary artery disease, early revascularization with CABG may be reasonable...
  28. doi Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome
    William E Boden
    Samuel S Stratton VA Medical Center, Albany Medical College, New York, USA
    Am J Cardiol 111:439-44. 2013
    ....
  29. ncbi DTCA for PTCA--crossing the line in consumer health education?
    William E Boden
    Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health, and Buffalo General Hospital, Buffalo, NY, USA
    N Engl J Med 358:2197-200. 2008
  30. ncbi Clinical utility of aVR-The neglected electrocardiographic lead
    Dmitriy Kireyev
    State University of New York at Buffalo, USA
    Ann Noninvasive Electrocardiol 15:175-80. 2010
    ..Several studies suggest that electrocardiographers tend to neglect lead aVR during the reading of electrocardiograms (ECGs). Our objective was to provide a systematic review of the most important diagnostic and prognostic uses of lead aVR...
  31. doi A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris
    Sabu Thomas
    Division of Cardiology, University of Rochester, 601 Elmwood Ave, Rochester, NY 14642, USA
    Can J Cardiol 29:472-82. 2013
    ....
  32. ncbi 50th Anniversary of the first successful permanent pacemaker implantation in the United States: historical review and future directions
    Hiroko Beck
    University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York, USA
    Am J Cardiol 106:810-8. 2010
    ..In conclusion, Greatbatch's historic achievement 50 years ago reminds us that technologic progress is timeless, as efforts to enhance clinical outcomes and the quality of life continue unimpeded into the 21st century...
  33. doi Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients
    Kulpreet Barn
    Department of Medicine, State University of New York, University at Buffalo, Buffalo General Hospital, Kaleida Health, Buffalo, NY 14203, USA
    Transpl Int 23:574-9. 2010
    ..In the low HDL group, the odds ratio for experiencing a MACE was 1.92. Therefore, HDL cholesterol may provide an important new therapeutic target to prevent vascular morbidity and mortality following renal transplantation...
  34. ncbi The corrected values for duration and frequency of angina at baseline in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial
    William E Boden
    Am J Cardiol 100:1604. 2007
  35. doi Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
    Leslee J Shaw
    Emory University School of Medicine, Atlanta, GA 30306, USA
    Circulation 117:1283-91. 2008
    ....
  36. doi Reducing post-myocardial infarction mortality in the elderly: the power and promise of secondary prevention
    William E Boden
    J Am Coll Cardiol 51:1255-7. 2008
  37. doi Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 156:185-92. 2008
    ....
  38. doi Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, MA 02115, USA
    JAMA 300:71-80. 2008
    ..Although an invasive strategy is frequently used in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), data from some trials suggest that this strategy may not benefit women...
  39. ncbi Effect of PCI on quality of life in patients with stable coronary disease
    William S Weintraub
    Christiana Care Health System, Newark, DE 19718, USA
    N Engl J Med 359:677-87. 2008
    ..It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease...
  40. ncbi Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists?
    Ravi K Yarlagadda
    J Am Coll Cardiol 40:1915-8. 2002
  41. ncbi An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  42. ncbi Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementatio
    Andra L Blomkalns
    Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0769, USA
    J Am Coll Cardiol 45:832-7. 2005
    ..We hypothesized that significant disparities in gender exist in the management of patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS)...
  43. ncbi Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: results of a randomized trial
    Paul G Barnett
    VA Palo Alto Health Care System, Palo Alto, Calif, USA
    Circulation 105:680-4. 2002
    ..The effects of these strategies on economic outcomes have not been established...
  44. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
    ....
  45. ncbi Surgery, angioplasty, or medical therapy for symptomatic multivessel coronary artery disease: is there an indisputable "winning strategy" from evidence-based clinical trials?
    William E Boden
    J Am Coll Cardiol 43:1752-4. 2004
  46. ncbi Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non-ST-segment elevation acute coronary syndrome
    William E Boden
    Am J Cardiol 93:69-72. 2004
  47. ncbi Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, Mass, USA
    Am Heart J 146:764-74. 2003
    ..In addition, we will consider appropriate methods/venues for use of GP IIb/IIIa receptor antagonism, including its role in an "early invasive" catheterization strategy...
  48. ncbi "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era
    William E Boden
    Division of Cardiology and the Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut 06102, USA
    J Am Coll Cardiol 41:113S-122S. 2003
    ..Optimal management should incorporate both strategies...
  49. ncbi Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave Myocardial Infarction Strategies In-Hospital (VANQWISH) Trial
    Frederick F Samaha
    Cardiovascular Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Cardiol 90:922-6. 2002
    ..76). No significant difference in outcomes between strategies was detected for a score > or =3. The TIMI risk score provides moderate incremental prognostic information in high-risk patients, during both short- and long-term follow-up...
  50. ncbi Is it time to reassess the optimal timing of coronary artery bypass graft surgery following acute myocardial infarction?
    William E Boden
    Am J Cardiol 90:35-8. 2002
  51. ncbi The role of pharmacotherapy and catheter-based intervention in the management of patients with non-ST-segment elevation acute coronary syndromes
    William E Boden
    Hartford Hospital, 80 Seymour Street, CT 06102, USA
    Curr Cardiol Rep 4:260-71. 2002
    ....
  52. ncbi Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 143:777-89. 2002
    ..However, no systematic review exists regarding the value of critical pathways in this setting...
  53. ncbi Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford, Connecticut 06102, USA
    Am J Cardiol 89:1300-2. 2002
  54. ncbi Stress test criteria used in the conservative arm of the FRISC-II trial underdetects surgical coronary artery disease when applied to patients in the VANQWISH trial
    Abhinav Goyal
    University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Coll Cardiol 39:1601-7. 2002
    ....
  55. ncbi Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials
    Shamir R Mehta
    Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada L6K 1B8
    JAMA 293:2908-17. 2005
    ....
  56. ncbi Acute coronary syndromes without ST-segment elevation--what is the role of early intervention?
    William E Boden
    N Engl J Med 353:1159-61. 2005
  57. ncbi Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial
    Maria Elenita Favarato
    Heart Institute InCor, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
    Int J Cardiol 116:364-70. 2007
    ..We evaluated the impact of Coronary Artery Bypass Graft Surgery (CABG), Percutaneous Coronary Intervention (PCI) or Medical Therapy (MT) on self-perceived quality of life among patients with stable Coronary Artery Disease (CAD)...
  58. ncbi Postpartum dissection of the left main coronary artery
    Ian S Rogers
    Department of Medicine, Boston University Medical Center, and Boston University School of Medicine, Boston, Massachusetts, USA
    Clin Cardiol 29:175-8. 2006
    ..Furthermore, once suspected, it is imperative that a definitive diagnostic study, that is, coronary angiography, be completed prior to the initiation of treatment whenever possible...
  59. ncbi The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
    Deborah B Diercks
    Department of Emergency Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA
    Am Heart J 152:140-8. 2006
    ..Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied...
  60. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  61. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  62. ncbi Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative
    Karen P Alexander
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 46:1479-87. 2005
    ..This study evaluated the impact of age on care and outcomes for non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  63. ncbi A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  64. ncbi The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status
    Christi Deaton
    The University of Manchester, Manchester, United Kingdom
    Heart Lung 35:315-23. 2006
    ..Coronary heart disease (CHD) and diabetes may have synergistic effects on symptoms, self-management, and general and cardiac-specific health status...
  65. ncbi Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424
    Leslee J Shaw
    Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90048, USA
    J Nucl Cardiol 13:685-98. 2006
    ....
  66. ncbi Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery
    David P Taggart
    Department of Cardiac Surgery, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Am Coll Cardiol 51:885-92. 2008
    ..We conclude that CABG should indeed remain the preferred revascularization treatment in good surgical candidates with unprotected LMS stenosis...
  67. ncbi Visual assessment of left ventricular perfusion and function with electrocardiography-gated SPECT has high intraobserver and interobserver reproducibility among experienced nuclear cardiologists and cardiology trainees
    Peter G Danias
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    J Nucl Cardiol 9:263-70. 2002
    ..We evaluated both intraobserver and interobserver agreement of interpretation of ECG-gated SPECT images among 3 cardiology trainees and 3 experienced nuclear cardiologists from 3 institutions...
  68. ncbi Letter by Mamkin et al regarding article, "weekend onset of acute myocardial infarction does not have a negative impact on outcome in Japan"
    Igor Mamkin
    Circ J 72:864; author reply 865. 2008
  69. ncbi Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects
    Isaac E Silverman
    Stroke Center, Hartford Hospital, University of Connecticut School of Medicine, CT, USA
    Conn Med 67:135-44. 2003
    ..We describe our initial experience at Hartford Hospital with a transcatheter PFO closure system and our multidisciplinary approach...
  70. ncbi Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial
    William S Weintraub
    Atlanta VA Medical Center, Decatur, GA, USA
    Am Heart J 151:1180-5. 2006
    ..A multilevel regression model will assess cost-effectiveness from a net benefit perspective. These approaches should provide the most detailed assessment available of the cost-effectiveness of PCI for coronary artery disease...
  71. ncbi Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes
    Karen P Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 155:1047-53. 2008
    ..To describe the association between transfusion and outcomes as a function of nadir hematocrit (HCT) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  72. ncbi Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy
    Peter G Danias
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 94:14-9. 2004
    ..Therefore, ECG-gated SPECT is very sensitive for detection of ischemic cardiomyopathy and CAD among patients with moderate to severe systolic dysfunction...
  73. ncbi Is there a gender paradox in the early invasive strategy for non ST-segment elevation acute coronary syndromes?
    Rachid A Elkoustaf
    Eur Heart J 25:1559-61. 2004
  74. ncbi Impact of fluid balance on incidence of atrial fibrillation after cardiothoracic surgery
    James S Kalus
    Department of Drug Information, Hartford Hospital, Connecticut 06102, USA
    Am J Cardiol 94:1423-5. 2004
    ..We also found that net fluid balance on postoperative day 2 was an independent predictor of postoperative AF among patients not receiving prophylactic therapy...